DelveInsight’s, “Uveal Melanoma Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Uveal Melanoma pipeline landscape. It covers the Uveal Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Uveal Melanoma Pipeline @ Uveal Melanoma Pipeline Outlook

Key Takeaways from the Uveal Melanoma Pipeline Report

• On May 13, 2026- Immatics US Inc. initiated a study’s purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
• On May 06, 2026- IDEAYA Biosciences announced a phase 3 study is divided into 2 cohorts of patients with primary uveal melanoma requiring either plaque brachytherapy or enucleation. In cohort 1, patients in the treatment arm will receive neoadjuvant darovasertib followed by plaque brachytherapy compared to immediate plaque brachytherapy (control arm). In cohort 2, the treatment arm will receive neoadjuvant darovasertib followed by definitive primary local therapy (i.e., plaque brachytherapy, proton beam radiation, or enucleation). Subjects in the control arm will go onto immediate enucleation.
• DelveInsight’s Uveal Melanoma Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Uveal Melanoma treatment.
• The leading Uveal Melanoma Companies such as Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceuticals, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co., GlaxoSmithKline, Janssenand others.
• Promising Uveal Melanoma Pipeline Therapies such as DYP688, Nivolumab, Relatlimab, ZIV-Aflibercept, Cemiplimab, IDE196, Crizotinib, Pembrolizumab, Binimetinib, Dacarbazine and others.

Get insights into Uveal Melanoma Clinical Trials, emerging therapies, and leading companies with DelveInsight @ Uveal Melanoma Treatment Drugs

Uveal Melanoma Overview

Uveal melanoma is the most common primary intraocular malignancy in adults. Intraocular is a disease in which malignant cells form in the tissues of the eye. Signs of intraocular melanoma include blurred vision or a dark spot on the iris. While development of uveal melanoma is largely considered to be a sporadic event, certain risk factors including light iris color, light skin color, ability to tan and others predispose individuals to Uveal melanoma. Tests that examine the eye are: Ophthalmoscopy, Slip-lamp examination, Gonioscopy and others have been used to help diagnose intraocular melanoma. A biopsy of the tumor is very rarely needed to diagnose intraocular melanoma. The treatment options include: Surgery, Thermotherapy, Radiation therapy, Coagulation.

Uveal Melanoma Emerging Drugs Profile

• BVD-523: BioMed Valley Discoveries Inc.

BVD-523 (ulixertinib), a novel targeted cytotoxic designed to inhibit ERK, can be used to treat cancers that harbor mutations in the MAPK signaling pathway. BVD-523, either alone or in combination with other drugs, will be a valuable strategy to safely treat cancers that exhibit abnormal MAPK pathway activity. BVD-523 clinical trials are being evaluated in phase II stage of development for the treatment of Uveal Melanoma.

• AU-011: Aura Biosciences, Inc.

AU-011 is being studied in phase II stage for the treatment of Uveal melanoma. Administration of AU-011 into the SC space (SCS) has potential benefits, including significantly higher concentration of drug in the tumor, which may improve certain treatment parameters. The drug has been granted Orphan drug designation and Fast track designation by U.S Food and Drug Administration.

• PAC-1: Vanquish Oncology

Procaspase Activating Compound-1 (PAC-1) is being evaluated in phase I/II stage for the treatment of Uveal Melanoma. PAC-1 is a apoptotic stimulant and Caspase 3 stimulant that acts as a central trigger point in the apoptotic pathway and is aberrantly elevated in many cancer types and when activated induces cancer cell death.

The Uveal Melanoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Uveal Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveal Melanoma Treatment.
• Uveal Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uveal Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveal Melanoma market

Explore groundbreaking therapies and clinical trials in the Uveal Melanoma Pipeline @ New Uveal Melanoma Drugs

Uveal Melanoma Companies

Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceuticals, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co., GlaxoSmithKline, Janssenand others.

Uveal Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Subcutaneous
• Intravenous
• Intramuscular

Uveal Melanoma Products have been categorized under various Molecule types such as

• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy

Learn about new Uveal Melanoma drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Uveal Melanoma Market Drivers and Barriers

Scope of the Uveal Melanoma Pipeline Report

• Coverage- Global
• Uveal Melanoma Companies- Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceuticals, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co., GlaxoSmithKline, Janssenand others.
• Uveal Melanoma Pipeline Therapies- DYP688, Nivolumab, Relatlimab, ZIV-Aflibercept, Cemiplimab, IDE196, Crizotinib, Pembrolizumab, Binimetinib, Dacarbazine and others.
• Uveal Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Uveal Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Uveal Melanoma Pipeline report today! @ Uveal Melanoma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Uveal Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Uveal Melanoma – DelveInsight’s Analytical Perspective
7. Mid Stage Products (Phase II)
8. Nivolumab: Bristol-Myers Squibb
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase I)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Preclinical)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Uveal Melanoma- Future Perspectives and Conclusion
17. Uveal Melanoma Analyst Views
18. Uveal Melanoma Key Companies
19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/uveal-melanoma-pipeline-insight